About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
GLMD - Galmed Pharmaceutica...| Previous Close | $3.67 | Open | $3.75 |
| Volume | 88.8K | Market Cap | 77.48M |
| Yield | Last Dividend |
| Galmed to add Open Label Part to ARMOR S... | 12/17/20 |
| TEL AVIV, Israel, Dec. 17, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceut... | |
| Galmed Pharmaceuticals Reports Third Qua... | 11/12/20 |
| TEL AVIV, Israel, Nov. 12, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceut... | |
| The Daily Biotech Pulse: Lilly's COVID-1... | 11/10/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 9) Alco... | |
| Galmed Pharmaceuticals to Report Third Q... | 11/05/20 |
| TEL AVIV, Israel, Nov. 5, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceuti... | |
| Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD... | 10/24/20 |
| Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) has earned an average rating of ???Buy??? from the eleven research firms that are presently covering the com... | |
| Global Non-Alcoholic Steatohepatitis Man... | 10/23/20 |
| ???Global Non-Alcoholic Steatohepatitis Management Market???Industry Trends and Forecast to 2026??? New Research Report Added to Databridgemarketresea... | |
| Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD... | 10/21/20 |
| Wall Street brokerages predict that Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) will report ($0.32) earnings per share for the current quarter, Zacks In... | |
| Non-alcoholic Steatohepatitis Market Wil... | 10/13/20 |
| Non-alcoholic Steatohepatitis Market By Drug Type (Vitamin E & Pioglitazone, Ocaliva, Elafibranor, Selonsertib & Cenicriviroc, Obeticholic acid, Other... | |
| Galmed Pharmaceuticals Provides Business... | 08/06/20 |
| TEL AVIV, Israel, Aug. 6, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceuti... | |
| Galmed Pharmaceuticals Announces Acceler... | 08/06/20 |
| TEL AVIV, Israel, Aug. 6, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceuti... | |
| Galmed Pharmaceuticals to Report Second ... | 07/30/20 |
| TEL AVIV, Israel, July 30, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceut... | |
| How Galmed (GLMD) Stock Stands Out in a ... | 06/10/20 |
| Galmed (GLMD) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well. | |
| Galmed Pharmaceuticals Provides Business... | 05/14/20 |
| TEL AVIV, Israel, May 14, 2020 /PRNewswire/ --Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutic... | |
| Galmed Pharmaceuticals to Report First Q... | 05/07/20 |
| TEL AVIV, Israel, May 7, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutic... | |
| The Daily Biotech Pulse: Mylan Ramps Up ... | 03/20/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 19.) ... | |
| The Daily Biotech Pulse: Pfizer's Eczema... | 03/19/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18)... | |
| Earnings Scheduled For March 12, 2020 | 03/12/20 |
| Companies Reporting Before The Bell Dollar General Corporation (NYSE: DG ) is projected to report quarterly earnings at $2.02 per share on revenue of ... | |
| Galmed Pharmaceuticals Provides Business... | 11/06/19 |
| TEL AVIV, Israel, Nov. 6, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceuti... | |
| Galmed Pharmaceuticals to Report Third Q... | 10/30/19 |
| TEL AVIV, Israel, Oct. 30, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceut... | |
| The Daily Biotech Pulse: Therapix Extend... | 10/11/19 |
| The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs O... | |
| The Daily Biotech Pulse: UCB To Buy Ra P... | 10/10/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 9) A... | |
| The Daily Biotech Pulse: Sanofi's Dupixe... | 08/06/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks No biotech stocks hit 52-week highs Monday. Down I... | |
| Madrigal, Galmed, And Galectin In Phase ... | 05/22/19 |
| No summary available. | |
| Galmed Pharmaceuticals Ltd. (GLMD) CEO A... | 05/07/19 |
| No summary available. | |
| Galmed beats by $0.04 | 05/07/19 |
| No summary available. | |
| NASH players in the red as EASL announce... | 04/11/19 |
| No summary available. | |
| IPO Update: Genfit Files Proposed Terms ... | 03/19/19 |
| No summary available. | |
| Galmed Pharmaceuticals Ltd. (GLMD) CEO A... | 03/13/19 |
| No summary available. | |
| Galmed FY 2018 top line up 82% | 03/13/19 |
| No summary available. | |
| Galmed Pharmaceuticals (GLMD) Reports Q4... | 03/13/19 |
| https://www.investing.com/analysis/galmed-pharmaceuticals-glmd-reports-q4-loss-misses-revenue-estimates-200397199 | |
| Strong Buy rating | 01/08/21 |
| Raymond James maintains Outperform rating and lowers Price Target from $20.00 to $17.00 | |
| Buy rating | 11/25/20 |
| Canaccord Genuity maintains Buy rating and lowers Price Target from $25.00 to $20.00 | |
| Date | 2020-11-12 (BMO) | Est. (EPS/Rev.) | ($0.30)/ 0 |
| Actual (EPS/Rev.) | $-0.32/ | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| RenHen Investments | RenHen Investments | 67.00 % | Follow |
| Biotech picks | mr jackson | 50.00 % | Follow |
| British Bull Trader | John Drummond | 27.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
